Patents by Inventor George D. Hartman

George D. Hartman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mitotic kinesin inhibitors
    Patent number: 7348440
    Abstract: The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: March 25, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth L. Arrington, Paul J. Coleman, Christopher D. Cox, Mark E. Fraley, Robert M. Garbaccio, George D. Hartman, William F. Hoffman, Edward S. Tasber
  • Prodrugs of mitotic kinesin inhibitors
    Patent number: 7329762
    Abstract: The present invention relates to phosphate ester prodrugs of dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: June 8, 2004
    Date of Patent: February 12, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Robert M. Garbaccio, George D. Hartman, William F. Hoffman
  • Tyrosine kinase inhibitors
    Patent number: 7265134
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: September 4, 2007
    Assignee: Merck & Co., Inc.
    Inventors: George D. Hartman, Thomas J. Tucker, John T. Sisko, Anthony M. Smith, William C. Lumma, Jr.
  • Substituted pyrazolo[3,4-d] pyrimidinones as a mitotic kinesin inhibitor
    Patent number: 7262186
    Abstract: The present invention relates to azolopyriniidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: August 28, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, George D. Hartman, William F. Hoffman
  • Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor
    Patent number: 7262187
    Abstract: The present invention relates to azolopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: August 28, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, George D. Hartman, William F. Hoffman
  • Substituted furopyrimidinones as a mitotic kinesin inhibitors
    Patent number: 7244723
    Abstract: The present invention relates to furanopyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: July 17, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, George D. Hartman
  • Mitotic kinesin inhibitors
    Patent number: 7235580
    Abstract: The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: June 26, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Michael J. Breslin, Paul J. Coleman, Christopher D. Cox, George D. Hartman, Brenda J. Mariano
  • Tyrosine kinase inhibitors
    Patent number: 7186723
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: March 6, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Jennifer P. Peckham, William F. Hoffman, Kenneth L. Arrington, Mark E. Fraley, George D. Hartman, Yuntae Kim, Barbara Hanney, Keith L. Spencer
  • Tyrosine kinase inhibitors
    Patent number: 7169788
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: January 30, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Kenneth L. Arrington, Mark E. Fraley, George D. Hartman
  • Tyrosine kinase inhibitors
    Patent number: 7115597
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: October 3, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman, Jacob M. Hoffman, Jr., John T. Sisko, Peter J. Manley, Anthony M. Smith, Thomas J. Tucker, William C. Lumma, Jr., Leonard Rodman
  • Tyrosine kinase inhibitors
    Patent number: 7109204
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: September 19, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Fraley, Kenneth L. Arrington, William F. Hoffman, George D. Hartman, Jennifer P. Peckham
  • Benzazepinone alpha vintegrin receptor antagonists
    Patent number: 7109191
    Abstract: The present invention relates to novel benzazepinone derivatives, their synthesis, and their use as ?v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors ?v?3 and ?v?5 and are therefore useful for inhibiting bone resorption, treating and/or preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
    Type: Grant
    Filed: April 29, 2002
    Date of Patent: September 19, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Robert S. Meissner, Paul J. Coleman, Mark E. Duggan, George D. Hartman, Jiabing Wang, John H. Hutchinson
  • Tyrosine kinase inhibitors
    Patent number: 6958340
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: October 25, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Peter J. Manley, Adrienne Balitza, George D. Hartman, Leonard Rodman
  • Tyrosine kinase inhibitors
    Patent number: 6927293
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: August 26, 2002
    Date of Patent: August 9, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Yuntae Kim, Barbara Hanney, Keith L. Spencer, George D. Hartman, Kenneth L. Arrington
  • (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors
    Patent number: 6875767
    Abstract: The present invention relates to compounds having the formula I: which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions. The compounds of the present invention are useful in treating angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Grant
    Filed: June 19, 2002
    Date of Patent: April 5, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, George D. Hartman
  • Tyrosine kinase inhibitors
    Publication number: 20040242637
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 17, 2004
    Publication date: December 2, 2004
    Inventors: George D Hartman, Thomas J Tucker, John T Sisko, Anthony M Smith, William C Lumma
  • Tyrosine kinase inhibitors
    Publication number: 20040235867
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: January 23, 2004
    Publication date: November 25, 2004
    Inventors: Mark T. Bilodeau, Peter J. Manley, George D. Hartman
  • Tyrosine kinase inhibitors
    Publication number: 20040235875
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: January 29, 2004
    Publication date: November 25, 2004
    Inventors: Mark E. Fraley, Kenneth L Arrington, William F Hoffman, George D Hartman, Jennifer P Peckham
  • Tyrosine kinase ihnibitors
    Publication number: 20040235826
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: February 24, 2004
    Publication date: November 25, 2004
    Inventors: Jennifer P. Peckham, William F. Hoffman, Kenneth L. Arrington, Mark E. Fraley, George D. Hartman, Yuntae Kim, Barbara Hanney, Keith L. Spencer
  • Tyrosine kinase inhibitors
    Publication number: 20040220216
    Abstract: The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
    Type: Application
    Filed: March 15, 2004
    Publication date: November 4, 2004
    Inventors: Kenneth L Arrington, Mark E. Fraley, George D. Hartman